Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Bayer seeks German thiacloprid report injunction

Bayer CropScience has applied for an injunction against what it terms inaccurate reports on two of its thiacloprid-based garden insecticide products. The German publisher Bund stated that the active ingredient was “harmful to bees” in a pesticide guidebook and repeated the claim in a press release and on its website towards thiacloprid products, Calypso and Lizetan, Bayer notes. Studies show that “thiacloprid is not toxic to bees when applied properly”, it maintains. The company complains that the “undifferentiated statement regarding the danger to bees from Calypso and Lizetan creates a false impression with consumers and is therefore grossly misleading”. Bayer adds that the Bund’s statement that its labelling amounts to suspected conscious consumer deception amounts to a “grossly false assumption because both formulations follow legal requirements”. Both products are registered and classified as “not toxic to bees” in Germany, Bayer notes. The Bund is to make statement at a German court on the injunction this month.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts